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Abstract
Vasoactive intestinal peptide (VIP) is a multifunctional neuropeptide with demonstrated immunosuppressive and
neuroprotective activities. It has been shown to inhibit Amyloid beta (Ab)-induced neurodegeneration by indirectly
suppressing the production and release of a variety of inflammatory and neurotoxic factors by activated microglia. We
demonstrated that VIP markedly increased microglial phagocytosis of fibrillar Ab42 and that this enhanced phagocytotic
activity depended on activation of the Protein kinase C (PKC) signaling pathway. In addition, VIP suppressed the release of
tumor necrosis factor alpha (TNF-a) and nitric oxide(NO) from microglia activated by combined treatment with fibrillar Ab42
and low dose interferon-c (IFN-c). We utilized an adenovirus-mediated gene delivery method to overexpress VIP
constitutively in the hippocampus of APPswPS1 transgenic mice. The Ab load was significantly reduced in the hippocampus
of this animal model of Alzheimer’s disease, possibly due to the accumulation and activation of cd11b-immunoactive
microglial cells. The modulation of microglial activation, phagocytosis, and secretion by VIP is a promising therapeutic
option for the treatment of Alzheimer’s disease(AD).
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Introduction
Alzheimer’s disease is a progressive neurodegenerative disease
characterized by senile plaques, intracellular neurofibrillary
tangles, and reactive gliosis involving both microglia and astrocytes
[1,2]. Microglia are derived from mononuclear phagocytes and
function as the resident macrophage-like cells of the brain
parenchyma. Microglia serve functions similar to other resident
macrophages, including phagocytosis, antigen presentation and
production of cytokines. Microglia-mediated immune responses
play both protective and deleterious roles in the pathogenesis of
AD. On one hand, microglia secrete neurotrophic agents and
eliminating beta-amyloid through direct phagocytosis. Conversely,
microglia release neurotoxic (pro-inflammatory) cytokinase and
other factors that can cause neurodegeneration, including NO.
Therapeutic strategies that inhibit the secretion of neurotoxins
from microglia or enhance microglial phagocytic activity may
reduce cerebral Ab load in mouse models of AD and thus limit
neurodegeneration [3–6].
Several endogenous brain mechanisms serve to dampen
inflammatory responses in the brain. As one group of critical
anti-inflammatory agents, neuropeptides maintain the immuno-
logical privilege of the central nerve system (CNS) [7]. For
example, calcitonin gene-related peptide [8], adrenomedullin [9],
neuropeptide Y [10] and somatostatin [11] are anti-inflammatory
immune modulators. Several recent studies indicated that
vasoactive intestinal peptide can also modulate immune function
through G-protein coupled receptors expressed by immune cells
and that VIP signaling is an important component of a
homeostatic neuroimmune control system [12][13].Vasoactive
intestinal peptide is a 28-amino acid peptide secreted by
peptidergic neurons located in all regions of the cerebral cortex,
limbic forebrain (septum, amygdala, hippocampus, and stria
terminalis) and hypothalamic areas (paraventricular and periven-
tricular nuclei, arcuate nucleus, and anterior and preoptic areas).
It is believed that VIP-containing nerve terminals constitute an
anatomical link between the CNS and immune system [14–16].
Vasoactive intestinal peptide exerts anti-inflammatory effects on
microglia by activating two common VIP receptors: VPAC1 and
VPAC2. These receptors stimulate adenylate cyclase (AC), which
increases intracellular cyclic adenosine monophosphate (cAMP)
concentrations and leads to downstream activation of protein
kinase A (PKA) and PKA-responsive transcription factors. The
release of pro-inflammatory TNF-a, interleukin(IL)-1b, IL-6, NO
from bacterial lipopolysaccharide (LPS)-activated primary microg-
lial cultures was marked reduced by 10
28 M VIP [17][18].
Lipopolysaccharide and interferon gamma (IFN-c)-activated
microglia also produced less macrophage inflammatory protein
(MIP)-2, MIP-1a, keratinocyte derived chemokine (KC),
RANTES (regulated upon activation normal T cell expressed
and secreted protein and c-interferon inducible protein (IP-10) in
response to VIP treatment [17] [19]. Thus, VIP stimulation of
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proinflammatory chemokines and cytokines. Expression of VIP
is significantly decreased in the cerebral cortex of aged animals
and VIP blockade in younger animals resulted in impaired
learning and memory [20–21].
In addition, VIP secretion was significant reduced in the insular
and angulate cortex of AD patients as measured by radioimmu-
noassay [22], while the number of neurons expressing VIP was
significantly reduced in the suprachiasmatic nucleus of female pre-
senile AD patients [23]. It is still unclear, however, whether this
reduction was the cause or the result of cortical deterioration and
AD-related cognitive decline. A recent study did manage to show
that VIP inhibited Ab-induced neurodegeneration by indirectly
inhibiting the production of a battery of inflammatory and
neurotoxic agents by activated microglia cells [24], suggesting that
a VIP deficit may contribute to AD-associated focal cortical
degeneration. Whether VIP treatment to the brain can improve
AD pathogenesis has still not been demonstrated. Furthermore,
increased phagocytic capacity of microglia after VIP treatment, a
possible mechanism to reduce cerebral Ab load, has also not been
directly observed.
The present study investigated the effect of VIP on the
phagocytosis of Ab by microglia and on the secretion of
proinflammatory cytokines by microglia in response to Ab.T o
demonstrate the beneficial effect of VIP in vivo, we overexpressed
VIP in transgenic PS1/APP mice and examined whether this
treatment could decrease brain Ab load in this AD model.
Results
VIP promote phagocytosis of fibrilized Ab1–42 by
activated murine microglial cells
We first examined the effects of VIP on the phagocytic functions
of mouse primary microglial cells. To determine if VIP can
modulate microglial uptake of Ab1–42, mouse primary microglial
cells were incubated in 500 nM fibrilized-Cy3-Ab1–42 for 2 h in
the presence or absence of VIP. Cell supernatants and lysates were
analyzed for extracellular and cell-associated Cy3-Ab42 using a
fluorometer (Fig. 1A, B). Co-incubation with VIP significantly
enhanced microglial phagocytosis of Ab1–42 peptide as evidenced
by the increase in cell-associated Cy3-Ab42 fluorescence (Fig. 1A,
top panel) and the significant reduction in extracellular Cy3-Ab42
(Fig. 1A, bottom panel). As a control for the non-phagocytic
incorporation of Ab1–42 by microglia, microglial cells were
incubated at 4uC under the same treatment conditions. As a
positive control, Cy3-Ab42 uptake was measured in the presence of
the ubiquitous microglial activator LPS; indeed LPS increased
microglial phagocytic Cy3-Ab42 uptake (Fig. 1A, top panel) and
reduced extracellular Cy3-Ab42 (Fig. 1A, bottom panel, P,0.05).
We next assessed the effect of different VIP doses on microglial
phagocytosis of fibrilized-Ab1-42. Phagocytotic uptake was depen-
dent on VIP dose, with maximal intracellular Cy3-Ab42 at
10
26 M (Fig. 1B, P,0.05). This enhanced Ab42 phagocytosis
was verified by a quantitative immunofluorescence assay. Cultures
were incubated in fluorescence-tagged Ab42 in the presence and
absence of VIP. Cultured microglia exhibited significantly higher
intracellular fluorescence when cultured in the presence of VIP
(Fig. 1C).
PKC inhibitors attenuate VIP-enhanced phagocytosis of
fibrilized-Ab42 by microglia
Delgado et al. found that the stimulatory effect of VIP on freshly
isolated resting macrophages was mediated by the PKC signaling
pathway [25]. To examine the signal pathways involved in VIP-
mediated stimulation of microglial phagocytosis of fibrilized-Ab42,
microglial cultures were treated with VIP for 2 hr in the presence of
the myristoylated protein kinase C peptide inhibitor or the PKA
inhibitor fragment 14–22, myristoylated trifluoroacetate salt. In
parallel experiments, microglial cultures were treated with the PKC
agonist PMA or the adenyly cyclase/PKA pathway activator
forskolin. Forskolin treatment alone did not enhance Cy3-Ab42
phagocytosis compared to controls. In contrast, PKC activation by
PMA increase microglia phagocytic activity compared to controls.
The PKC pathway inhibitor myristoylated protein kinase C peptide
inhibitor abolished the increased phagocytosis of Cy3-Ab42 induced
by VIP, while the PKA inhibitor fragment 14–22 had no effect
(Fig. 2 A.B). These data suggest that activation of the PKCpathway,
but not the PKA pathway, is necessary for the VIP-induced
enhancement of Cy3-Ab42 phagocytosis by microglial cells.
VIP inhibits Ab42-activated TNF-a and NO secretion from
murine microglial cells
Activated microglia can be either neuroprotective or neurodes-
tructive depending on the phase of activation. VIP may promote
neuroprotection against Ab toxicity by promoting phagocytosis.
To examine whether VIP also altered the secretion of neurotoxic
cytokines or oxidant species, the levels of TNF-a and NO were
measured in the supernatant of activated microglia in the presence
and absence of VIP. Murine primary microglial cells were
activated with either fibrilized Ab1–42 (2.5 mM) alone or fibrilized
Ab1–42 combined with low dose IFN-c (10 U/ml) for 24 h in the
absence or presence of VIP. The secretion of TNF-a and NO were
analyzed by ELISA. Low dose IFN-c plus Ab1–42 evoked a robust
increase in TNF-a and NO secretion [26]. Treatment with VIP
alone (10
28 M) did not affect basal TNF-a and NO secretion from
resting microglia (Fig. 3A.B) but inhibited TNF-a and NO
secretion induced by Ab plus low dose IFN-c (Fig. 3A.B, P,0.01).
Similar results were obtained in the murine microglial cell line N9
cells (data not shown). Thus, VIP could enhance phagocytosis of
Ab42 by activated microglia and inhibit the release of neurotoxic
TNF-a and NO by Ab42-activated microglia.
Adenovirus-mediated VIP expression reduces
immunoreactive Ab deposits and fibrillar Ab deposits in
the hippocampus but not in the neocortex of AD mice
We next determined whether VIP treatment could affect Ab
plaque formation and accumulation in a mouse model of
Alzheimer’s disease. Since exogenous VIP is rapidly degraded
[27], we adopted viral vectors for sustained and local expression of
a VIP transgene. We constructed a recombinant adenovirus vector
encoding functional VIP, Ad-VIP (Fig. 4A), as described
previously [28]. The infectious titer of the Ad-VIP vector was
1.0610
11 pfu/mL. Expression of VIP protein was determined in
virus-infected 293 cells. Typically, 2610
2 particles of Ad-VIP
vector/cell resulted in an almost 20-fold increase of VIP in the
culture medium per 10
6 infected 293 cells (Fig. 4C).
We then stereotaxically injected the recombinant fluorescence-
labeled adenovirus Ad-VIP into the right lateral ventricle of 10
month old PS1/APPsw mice (expressing mutant APP and PS1). A
control group of PS1/APPsw mice were injected with a blank
recombinant adenovirus, Ad-Blank, or with PBS. After two
months, mice were sacrificed and VIP expression was quantified
by red fluorescence distribution and intensity. Widespread and
intense fluorescence was observed in the dentate gyrus (DG).
Combined staining of neuronal cell bodies with NeuN revealed
that Ad-VIP could be efficiently expressed in DG granule and
hilar neurons for as long as two months (Fig. 4D).
VIP Reduce Ab Load in AD Transgenic Mice
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e29790Figure 1. VIP treatment promote microglial phagocytosis of fibrillar Ab1–42. A: Cell supernatants and lysates were analyzed for cell-
associated (top panel) and extracellular (bottom panel) Cy3-Ab1–42 using a fluorometer. Data are represented as the relative fold of mean
fluorescence change (mean6SD), calculated as the mean fluorescence for each sample at 37uC divided by mean fluorescence at 4uC (n=5 for each
condition presented). One-way ANOVA followed by post-hoc comparison showed a significant between-group difference (*P,0.05, **P,0.01
compared with control). B: Primary microglia cells were stimulated with fibrillar Ab1–42 (500 nM) in the absence or presence of different
concentrations of VIP(2logM). Cell supernatants and lysates were analyzed. for cell-associated (right panel) and extracellular (left panel) Cy3-Ab1–42
using a fluorometer (n=5 for each condition presented). C: Mouse primary microglial cells were seeded in twelve-well tissue-culture plates (2610
5/
well) and treated with 500 nM Cy3-Ab1–42 in the presence or absence of VIP(10
28 M), LPS (100 ng/ml, as positive control). After 2 hr, these cells were
washed and fixed (see Materials and Methods). Subsequently, immunofluorescence microscopy examination was performed with a 610 objective
with appropriate filter selection. The up panels show Cy3-Ab1–42 associated with microglial cells under the various treatment conditions. The below
panels (DAPI) reveal the presence of the microglia cell as identified by their nuclei.
doi:10.1371/journal.pone.0029790.g001
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expression in reducing Ab load in the brain, diffuse and fibrillar
Ab deposits were detected by immunohistochemistry using the
anti-Ab 6E10 antibody and quantified by morphometry (Fig. 5A,
a–c and 5B). The amyloid load was expressed as the percent area
showing Ab immunoreactivity. The average Ab load in hippo-
campus was 0.3960.09% in the Ad-VIP-injected group, signifi-
cantly lower than in either the Ad-Blank group (0.6560.15%) or
the PBS-injected group (0.7060.06%) (Fig. 6B). Thus, Ad-VIP
injection reduced the Ab load in the hippocampus by approx-
imately 40% compared to the blank vector (P=0.04, n=8 for
each group). In the neocortex, however, the average amyloid load
in Ad-VIP-injected mice (1.2560.10%) not significantly less than
in Ad-blank-injected mice (1.3460.17%) or PBS-injected mice
(1.3260.15%) (Ad-VIP vs. PBS, P=0.66).
Fibrillar Ab deposits were detected by thioflavin S staining and
quantified by morphometric analysis (Fig. 5A, d–f and 5C). Again,
the Ab loads were quantified by the average percent area showing
thioflavin S fluorescence. The average hippocampal Ab load in Ad-
VIP-injected mice (0.3960.03%) was significantly lower than in Ad-
blank-injected mice (0.5360.03%) and PBS-injected mice
(0.5760.04%). Thus, Ad-VIP injection reduced thioflavin S staining
in the hippocampus by approximately 25% compared to Ad-blank
injection (P=0.01, n=8 for each group). Inthe neocortex, there was
no difference in the Ab load as measured by thioflavine S
fluorescence between any of the mouse treatment groups (Fig. 5C).
We further determined the levels of buffer-soluble and in-
soluble Ab in the treatment groups by Ab40- and Ab42-specific
sandwich ELISAs. In the hippocampus, the buffer-soluble Ab42
content in Ad-VIP-injected mice (45.9762.57 pg/mg protein) was
significantly lower than in Ad-blank-injected mice (61.6564.5 pg/
mg protein) and PBS-injected mice (57.2966.48 pg/mg protein)
(Figure 6A). Injection of Ad-VIP reduced the buffer-soluble Ab42
level in the hippocampus by approximately 27% compared to Ad-
Figure 2. PKC inhibitor attenuates VIP promotion of microglial phagocytosis of fibrillar Ab1–42. A: Mouse primary microglial cells were
seeded in twelve-well tissue-culture plates (2610
5/well) and treated with 500 nM Cy3-Ab1–42 in the presence of VIP(10
28 M), PMA (30 nM), Forskolin
(10 mM), Myristoylated protein kinase C peptide (50 mM) combined with VIP, PKA inhibitor fragment 14–22 myristoylated trifluoroacetate salt (PKA
Inhibitor) (5 mM) combined with VIP. After 2 hr, these cells were washed and fixed (see Materials and Methods). Subsequently, immunofluorescence
microscopy examination was performed with a 610 objective with appropriate filter selection. The up panels show Cy3-Ab1–42 associated with
microglial cells under the various treatment conditions. The below panels (DAPI) reveal the presence of the microglia cell as identified by their nuclei.
B: Mouse primary microglial cells were seeded in twelve-wells tissue-culture plates (2610
5/well) and treated with 500 nM Cy3-Ab42 in the presence or
absence of VIP and Myristoylated protein kinase C peptide inhibitor, PMA (PKC pathway activator), cAMP agonists(Forskolin), PKA antagonists(PKA
inhibitor fragment 14–22, myristoylated trifluroacetate salt)for 2 hr, Subsequently, Cell supernatants and lysates were analyzed for cell-associated
(top panel) and extracellular (bottom panel) Cy3-Ab1–42 using a fluorometer. Data are represented as the relative fold of mean fluorescence change
(mean6SD), calculated as the mean fluorescence for each sample at 37uC divided by mean fluorescence at 4uC (n=5 for each condition presented).
One-way ANOVA followed by post-hoc comparison showed a significant between-group difference (*P,0.05, **P,0.01 compared with control).
doi:10.1371/journal.pone.0029790.g002
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soluble Ab40 content in Ad-VIP-injected transgenic mice
(44.0463.98 pg/mg protein, n=7) was also significantly lower
than in Ad-Blank-injected mice (66.9067.86 pg/mg protein,
n=7,P=0.03) (Fig. 6B). The buffer-insoluble Ab42 and Ab40 in
Ad-VIP-injected mice (74.8265.88 ng/mg protein and
61.1565.36 ng/mg protein, respectively) was moderately reduced
compared to the Ad-blank-injected mice (89.3265.04 ng/mg
protein, 76.5068.27 ng/mg protein, respectively) and PBS-
injected mice (85.1965.31 ng/mg protein,74.2462.92 ng/mg
protein, respectively), but the difference did not reach statistical
significance (Ad-VIP vs. Ad-Blank, P=0.13 for insoluble Ab42,
P=0.12 for insoluble Ab40) (Fig. 6C, D).
In the neocortex, buffer-soluble Ab42 in Ad-VIP-injected mice
(45.7165.41 pg/mg protein) was not significantly lower than in
Ad-blank-injected mice (48.1866.91 pg/mg protein) or PBS-
injected mice (50.9464.43 pg/mg protein) (Ad-VIP vs. PBS,
P=0.47). There was no difference in the insoluble Ab42 or
insoluble Ab40 between any treatment groups (Fig. 6C).
Ad-VIP injection activated CD11b-immunoreactive
microglial in the hippocampus, but not CD11c- or CD45-
immunoreactive microglia
The role of microglial activation in Ab plaque reduction in PS1/
APPsw mice was investigated by immunofluorescence labeling
(Fig. 7). The average CD11b immunoreactive area in the
hippocampus was 0.2160.03% in Ad-VIP-injected mice,
0.1460.03% in Ad-Blank-injected mice, and 0.1160.03% in mice
injected with PBS (Fig. 7A, a–c, 7B). Thus, Ad-VIP injection
enhanced the accumulation of CD11b-immunoreactive microglial
cells in the hippocampus by approximately 50% compared to Ad-
Blank injection (P=0.003, n=8 for each group). However, the
numbers of CD11c-immunoreactive microglial cells were not affected
significantly as indicated by the lack of change in immunoreactive
areas (0.1060.012%, 0.1260.007% and 0.1060.014% for mice
injected with Ad-VIP, Ad-Blank, and PBS, respectively; Fig. 7A,d–f,
7C). We also investigated CD45-immunoreactive microglial cells to
investigate the activation stage of microglia in these transgenic mice.
Figure 3. VIP inhibite TNF-a or NO secretion induced by Ab1–42 ((2.5 mM) combined with low dose IFN-c (10 U/ml) in microglial cells.
Microglial cells were plated in 24-well tissue-culture plates at 1610
5 cells per well and stimulated for 24 hr with either Ab1–42 (2.5 mM) or a dose range
of 10 U/mL IFN-c (IFN low), 200 U/mL IFN-c (IFN high)/Ab1–42 (2.5 mM) in the presence or absence of VIP (10
28 M). Cell-free supernatants were
collected and subjected to TNF-a ELISA or Nitrite Determination Griess Reagent Kit as indicated. Data are the mean6SD of three separate
experiments performed in double duplicate. ANOVA and post hoc testing revealed significant differences between different group. **P,0.01 Ab1–42/
IFN-c treated samples plus VIP vs. Ab1–42/IFN-c treated samples.
doi:10.1371/journal.pone.0029790.g003
VIP Reduce Ab Load in AD Transgenic Mice
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not significantly different between injection groups (0.1360.013%,
0.1460.009% and 0.1260.012%formiceinjectedwithAd-VIP,Ad-
Blank, and PBS, respectively; Fig. 7A g–i, 7D), consistent with the
lack of change in CD11c staining.
Recombinant adenovirus-mediated VIP brain delivery
does not increase gliosis and apoptosis in APP/PS1
transgenic mice
High levels of VIP expression activated microglial cells, which
may also induce the secretion of neurotoxins (cytokines and NO),
leading to gliosis and apoptosis. To assess the cytotoxic potential
associated with recombinant adenovirus-mediated overexpression
of VIP, brain sections were subjected to Glial fibrillary acidic
protein (GFAP) immunohistochemistry and Terminal (TdT)-
mediated dUTP-biotin nick end labeling (TUNEL) assay. The
average GFAP immunoreactive area in the hippocampus was
4.4160.51% in the Ad-VIP group, 5.860.53% in the Ad-Blank
group, and 5.260.58% in the PBS group, indicating that VIP
overexpression slightly reduced gliosis compared to Ad-blank
treatment, but not significantly (P=0.099, n=8 for each group)
(Fig. 8Aa–c). No apoptotic cell death was detected by TUNEL
Figure 4. VIP highly expressed in the hippocampus NeuN positive cells after unilateral lateral ventricular injection of Ad-VIP. A:
Schematic diagram of VIP adenovirus construction. B: Lane 1 shows the PCR product, corresponding to the mouse VIP cDNA (595 bp). Samples were
run on a 2% agarose gel with a DNA ladder (left side). VIP cDNA was also verified by sequencing. C: VIP expression in rAd5CMVhVIP-infected cells.
Culture media were assayed for VIP by an ELISA kit. Data shown are the total amount of VIP (ng) per 10
6 infected 293 cells (Multiplicity of infection
320) per 24 h. The results are representative of five experiments with 3 replicates. D: Brain sections were prepared from TgAPPswe/PS1dE9 mice two
months after Ad-VIP and subjected to double-immunofluorescence staining of VIP(red) and NeuN(green) using anti-VIP antibody and anti-NeuN
antibody. Ad-VIP injected brain showing widespread, high expression of VIP in the hippocampus and somewhat less expression in the neocortex(a,
d). NeuN staining showed with green fluorescence protein (b, e) and Merged picture showed(c,f). Scale bars 400 mm (a through c) and 200 mm( d
through f).
doi:10.1371/journal.pone.0029790.g004
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that adenovirus-mediated VIP overexpression in the hippocampus
does not induce neuronal or glial apoptosis.
Discussion
The principal pathological hallmark of Alzheimer’s disease is
the extracellular deposition of fibrillar Ab and its compaction into
senile plaques surrounded by activated microglia and astrocytes
(reactive gliosis). Microglial activation is a ‘‘double-edged’’ sword
in that these cells release proinflammatory cytokines, pro-apoptotic
factors and reactive oxygen and nitrogen species in addition to
protective neurotrophins. In addition, microglial phagocytosis can
protect neurons from toxic substances, such as aggregated Ab.
Regulating microglial phenotype to enhance protective mecha-
nisms (neurotrophin release and phagocytosis) while suppressing
neurotoxic effects could be the basis for novel therapeutic
strategies. Consistent with the role of neuropeptides as critical
modulators of the immune response in the CNS [29], we
demonstrated that VIP regulated microglial activation by
fibrilized-Ab42. Indeed, VIP significantly promoted microglia
phagocytosis of Ab1–42 and attenuated cerebral amyloidosis in a
transgenic mouse model of AD.
Previous studies examining the effects of VIP on phagocytosis in
macrophages yielded conflicting results. Delgado et al concluded
that a common denominator in these studies was that VIP
stimulated freshly isolated resting macrophages but inhibited
prestimulated macrophages. Therefore, the differences in the
reported studies could be due to the dominant cell population. In
addition, the stimulatory actions of VIP (whether for phagocytosis,
adherence and migration, or reactive oxygen production) appear
to be associated with PKC activity. Our experiment suggested that
the effect of VIP on phagocytosis of microglial cells trend to be
stimulatory and associated with PKC activity, Myristoylated
protein kinase C peptide inhibitor, which inhibit PKC pathway
could efficiently block this effect.
Figure 5. Adenovirus-mediated VIP expression reduces immunoreactive Ab deposits and fibrillar Ab deposits in the hippocampus
but not in the neocortex. (a through h) Two months after Ad-VIP, Ad-Blank, or PBS injection, mice were terminated and Ab deposits in the brain
were visualized by immunohistochemistry and thioflavine S staining quantified by morphometric analysis. Diffuse and fibrillar Ab deposits visualized
by 6E10 antibody (a through c) and thioflavine S staining (d through f) in the cerebral cortex and hippocampus from mice injected with PBS (a and d),
Ad-Blank (b and e) and Ad-VIP (c and f). The percentages of immunoreactive area for Ab and thioflavine S fluorescent, respectively, are shown as bar
graphs(g, h). The values shown are the mean6 S.E.M. Scale bars 400 mm (a through f). ANOVA and post hoc testing revealed significant differences
between different group. *P,0.05.
doi:10.1371/journal.pone.0029790.g005
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transgenic mouse induced significant VIP overexpression and
attenuated immunoreactive Ab deposits and fibrillar Ab deposits
in the hippocampus two months after injection. In contrast, Ab
levels in the cortex were not altered. These restricted of VIP effects
may be due to the limited expression of VIP outside the
hippocampus. To study the cellular mechanism of Ab clearance,
we measured changes in microglial and astrocytic immunoactivity.
Surprisingly, we found that CD11b-immunoreactive microglial
cells accumulated in the Ad-VIP-injected PS1/APP transgenic
mouse hippocampus relative to Ad-blank- or PBS-injected PS1/
APP transgenic mice, while CD11c-immunoreactive microglial
cells were not significantly altered by Ad-VIP-mediated VIP
overexpression. The activation of CD11b-positive microglial cells
may be due to VIP-induced activation of cAMP and PI-3K
signaling pathways [30]. A previous study demonstrated that
CD11b-positive microglial cells trend to have enhanced phagocy-
totic activity while CD11c-positive microglial cells trend to initiate
antigen presentation in response to cytokine secretion [6].
Recently, Nada Choucair-Jaafar reported that an antibody against
CD11b reduced the uptake of artificial amyloid deposits by
microglia, further indicating that CD11b+ microglia are involved
in Ab clearance [31]. These results may also partially explain why
the Ab load was reduced in the hippocampus of AD-VIP-treated
mice. In contrast, adenovirus-mediated VIP brain delivery did not
increase GFAP expression by astrocytes or neurocellular TUNEL
staining, indicating that VIP overexpression did not induce
astrogliosis or apoptosis in APP/PS1 transgenic mice. Thus,
recombinant adenovirus Ad-VIP injections may be a feasible and
safe treatment to promote the protective effects of microglial cells
without deleterious side effects.
In addition to promoting Ab accumulation, VIP also blocked
Ab-induced microglial TNF-a and NO secretion, consistent with
previous studies [24]. As a central inflammatory mediator, TNF-a
plays a key role in neuronal death mediated by activated
microglia. Elevated TNF-a levels were detected in the serum
and CSF of AD patients, as well as in cortical and glial cell cultures
after exposure to Ab. Furthermore, high levels of TNF-a induced
apoptosis of cortical neurons by activating the neuronal TNF-a
receptor [32,33]. Activated microglia also release NO, which can
form highly neurotoxic NO2
2. Weldon et al. demonstrated that
NO secreted by activated microglia could kill culture human fetal
neurons by apoptosis [34]. Many immune activators, such as LPS,
can promote microglial phagocytosis of Ab and reduce the Ab
load in transgenic mice [35]. However, most of these agents can
not inhibit concomitant microglial TNF-a or NO secretion, and
may even increase TNF-a and NO secretion, which abate the
possible clinical application. Recently, Delgado et al showed that
VIP efficiently inhibited the secretion of cytokines associated with
microglial activation induced by Ab [24]. Consider with Our study
that the presence of VIP resulted in a significant promotion of
microglial phagocytosis of fibrilized-Ab, hinting that VIP may be
an ideal treatment for AD.
Studies addressing the neuroprotective efficacy of VIP in a
Parkinson’s disease model revealed that VIP could prevent MPTP-
induced nigrostriatal dopaminergic neuronal death by blocking
microglial activation [36]. Furthermore, Gozes et,al found that the
Ab-induced cortical neuronal death was completely prevented by
Figure 6. Adenovirus-mediated VIP expression reduces soluble Ab42&A b40 in the hippocampus at 12 months of age. A, B: The buffer-
soluble Ab42 &A b40 contents in different treated Tg mice were quantified by ELISA. The results are shown as bar graphs (means6SEM pg/mg
protein). *P,0.05. C: D: The buffer-insoluble Ab42 contents in different treated Tg mice were quantified by ELISA. The results are shown as bar graphs
(means6SEM ng/mg protein).
doi:10.1371/journal.pone.0029790.g006
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injected intracerebroventricularly or delivered intranasally pre-
vented impairments in spatial learning and memory associated
with cholinergic blockade in a rat cholinergic deficits model [37].
Neuroinflammation may be a pathogenic mechanism common to
several neurodegenerative diseases, so VIP may be widely
applicable as a neuroprotective agent by suppressing the
pathological activities of activated microglia.
In summary, our results demonstrated that VIP promoted
microglia phagocytosis of Ab and suppressed the Ab-induced
release of microglial neurotoxins. Furthermore, constitutive
overexpression of VIP in the hippocampus reduced inflammation
and attenuated amyloidosis in a transgenic mouse model of AD.
Modulation of Ab-induced microglia activation and microglial
phenotype by delivery of VIP into the brain may be a novel
approach for the treatment of Alzheimer’s diseases.
Figure 7. CD11b but not CD11c or CD45 immunoreactive microglia significantly activated in the hippocampus of Ad-VIP injected
mice. A: (a–f) Brain sections from mice injected with PBS (a), Ad-Blank (b) and Ad-VIP (c) were stained with anti-CD11b antibody or anti-CD11c(d,e,f)
antibody or anti-CD45(g,h,i) antibody Scale bars are 200 mmi na through i. B: CD11b immunoreactive quantified by morphometric analysis. CD11b
immunoreactive area percentages in the hippocampus are shown as a bar graph (means 6 S.E.M.) *P,0.05. C: CD11c immunoreactive quantified by
morphometric analysis. CD11c immunoreactive area percentages in the hippocampus are shown as a bar graph (means 6 S.E.M.). D: CD45
immunoreactive quantified by morphometric analysis. CD1145 immunoreactive area percentages in the hippocampus are shown as a bar graph
(means 6 S.E.M.).
doi:10.1371/journal.pone.0029790.g007
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Reagents
b-Amyloid peptide(Ab)1–42, Cy3 conjugated Ab1–42 peptides
were purchased from Biosource International (Camarillo, CA). The
peptides were pre-aggregated for 24 h at 37uC in complete
medium. Vasoactive Intestinal Peptide was obtained from Sigma(S-
t.Louis, MO) and dissolved in 0.01 M phosphate-buffered saline
(PBS) to a stock concentrationof 10
26 M. Recombined mouse IFN-
c were purchased from BD Pharmigen(San Diego,CA).
Cell Cultures
The murine microglial cell line (N9) was kindly provided by Dr.
Ji Ming Wang (Center for Cancer Research, National Cancer
Institute, Frederick, USA) and were grown in RPMI 1640 medium
supplemented with 5% fetal calf serum, 2 mM glutamine,100 U/
mL penicillin, 0.1 g/mL streptomycin and 0.05 mM 2-mercapto-
ethanol.
Mouse primary microglial cells culture was prepared as
described previously [15]. Briefly, cerebral cortices from newborn
C57/BL6 mice (1–2 days old) were isolated under sterile
conditions and were kept at 4uC. Cells were mechanically
dissociated and plated in 75-cm
2 flasks, added RPMI 1640
medium supplemented with 5% fetal calf serum, 2 mM glutami-
ne,100 U/ml penicillin, 0.1 ug/ml streptomycin, and 0.05 mM 2-
mercaptoethanol. Primary cultures were kept for 14 days so that
only glial cells remained and microglial cells were isolated by
shaking flasks at 200 rpm in a Lab-Line incubator-shaker. More
than 98% of these glial cells stained positively for CD11b (BD
Pharmigen, San Diego, CA). All animals were provided by animal
center of Third Military Medical University and all experiments
were in compliance with protocols(IACUC: 06512) approved by
the Third Military Medical University Institutional Animal Care
and Use Committee.
Microglia Ab phagocytosis assays
Primary mouse microglia were seeded at 1610
5 cells/well (n=6
for each condition) in 24-well tissue culture plates containing
0.5 mL of complete RPMI 1640 medium. These cells were treated
for 2 h with ‘‘aged’’ Ab1–42 conjugated with Cy3 (Biosource
International; 500 nM pre-aggregated for 24 h at 37uCi n
complete medium). In the presence of Cy3-Ab1–42, microglial
cells were then treated with VIP, LPS. Some of these cells were
treated with PMA (30 nM), Forskolin (10 mM), Myristoylated
protein kinase C peptide (50 mM) combined with VIP, PKA
inhibitor fragment 14–22 myristoylated trifluoroacetate salt (PKA
Inhibitor) (5 mM)(Sigma, St.Louis, MO) combined with VIP in the
presence of Cy3-Ab1–42 for 2 h. Microglial cells were then rinsed
three times in complete medium, and the media were exchanged
with fresh complete medium for 10 minutes to allow for removal
of non-incorporated Ab1–42 and promote concentration of Ab1–42
into phagosomes. Extracellular and cell-associated Cy3-Ab1–42
were quantified using an MSF (SpectraMaxH, Molecular Devices)
with an emission wavelength of 590 nm and an excitation
wavelength of 543 nm.
A standard curve from 0 to 600 nM of Cy3-Ab was run for each
plate. Total cellular proteins were quantified using the Micro BCA
Protein Assay (Pierce, Rockford, IL). The mean fluorescence values
for each sample at 37uC and 4uC at the 2 h point were determined
by fluorometric analysis. Relative fold change values were
calculated as: mean fluorescence value for each sample at 37uC/
mean fluorescence value for each sample at 4uC. In this manner,
both extracellular and cellassociated Cy3-Ab1–42 were quantified.
Considering nonspecific adherence of Ab to the plastic surface of
culture plates, an additional control without cells was carried out
through all of experiments above. An incubation time of less than
4 h did not change the amount of Ab1–42 peptide detected in the
supernatant. In order to determine the extent to which cell death
might have influenced the phagocytic activity in the various
treatment groups, we performed the LDH assay on the relevant
supernatant. Data showed that there was no significant cell death
occurring over the 3 h time frame in any of the treatment groups.
Fluorescence microscope examination
Microglial cells (wild-type primary cultured microglial cells or
N9) phagocytosis of fibrillar Ab1–42bpeptides was carried out
Figure 8. Recombinant adenovirus-mediated VIP brain delivery does not increase gliosis and apoptosis. (a–f) Brain sections from mice
injected with PBS (a), Ad-Blank (b) and Ad-VIP (c) were stained with anti-GFAP antibody and Apoptotic cells identified by Tunel staining(d, e, f). Scale
bars are 200 mmi na through f.
doi:10.1371/journal.pone.0029790.g008
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were cultured at 2610
5/well in 12-well tissue-culture plates with
glass inserts for fluorescence microscopy. On the following day,
microglia cells were treated with Cy3-conjugated Ab1–42
(500 nM) in the presence or absence of VIP (10
28 M) for a
different phage of time. As a positive control, microglial cells
were treated with Cy3-conjugated Ab1–42 (500 nM) combined
with LPS(100 ng/mL, Sigma). In parallel dishes, microglial cells
were incubated with Cy3-conjugated Ab1–42 under the same
treatment conditions as described above, except that they were
incubated at 4uC to control for nonspecifically cellular
association of Cy3-Ab1–42. Microglial cells were then rinsed 3
times in Cy3-Ab1–42-free complete medium and the media was
exchanged with fresh Cy3-Ab1–42-free complete medium for
10 min both to allow for removal of non-incorporated Cy3-Ab1–
42 and to promote concentration of the Cy3-Ab1–42 peptide into
phagosomes. This medium was withdrawn, and microglia were
rinsed 3 times with ice-cold PBS. For fluorescence microscope
examination, these Microglial cells cells will be washed 5 times
with ice-cold PBS to remove extracellular Ab and fixed in 4%
paraformaldehyde(PFA) diluted in PBS, After three successive
rinses in TBS, microglia nuclei were detected by incubation with
DAPI for 10 min and finally mounted with fluorescence
mounting media containing Slow Fade antifading reagent
(Molecular Probes, Eugene, OR), and then viewed under a
BX61 microscope (Olympus, Tokyo, Japan) equipped with a
digital camera. The data was digitized using an attached Image
Pro Plus imaging system (MediaCybernetics).
Cytokine analysis
Microglial cells (N9 or wild-type primary cultured microglial
cells) were plated in 24-well tissue-culture plates (Costar, Cam-
bridge, MA) at 1610
5 cells per well and stimulated for 24 hr with
either Ab1–42 (2.5 mM) or a dose range of IFN-c (10 U/mL,
200 U/mL)/Ab1–42 (2.5 mM) in the presence or absence of VIP
(10
28 M). Cell-free supernatants were collected and stored at
270uC until analysis. TNF-a cytokine and NO levels in the
supernatants were examined using specific enzyme-linked immu-
nosorbent assay (ELISA) kits (R&D Systems) or Griess Reagent
Kit for Nitrite Determination (Promega) in strict accordance to the
manufacturer’s protocols. The results of TNF-a cytokine are
shown as mean picograms of each cytokine per milliliter (6SD)and
The results of NO represent as mean mM(6SD).
Recombinant adenovirus preparation
Recombinant adenovirus pAdeasy-VIP (1610
11 PFU/ml) and
blank adenovirus(1610
11 PFU/ml) was generated by Min Song
according to the methods [28] (Department of medical genetics,
Third Military Medical University), Briefly, VIP was amplified by
RT-PCR and cloned into a shuttle pAd Track-CMV vector with
Red florensence Protein (RFP) tag. This plasmid was linearized by
digesting with restriction endonuclease PmeI and subsequently
cotransformed into Escherichia coli BJ5183 cells with an
adenoviral backbone pAdEasy-1 plasmid. Recombinants were
selected by kanamycin resistance. Finally, recombinants were
transfected into HEK293 cells. Recombinant adenoviruses were
generated within 7–10 d. then purified with Sartbind Q5 column
purification system(Sartorius stedim biotech, Aubagne Cedex,
France). The titers of Adenovirus were determined by the
quantitative fluorescence assay as described previously [39]. A
control null Adenovirus (Ad-blank) which only express Red
florensence Protein was similarly prepared. VIP protein expression
was determined by ELISA kit (Peninsula Laboratories, San Carlos,
CA, USA), Typically, 2610
2 particles of Ad-VIP vector/cell
resulted in almostly 20-fold increase over background in the
culture medium per 10
6 infected 293 cells.
Experimental animals and stereotaxic injection of Ad-VIP
Tg(APPswe, PSEN1de9) mice (line B6C3-85Dbo/J) were
purchased from Jackson Laboratory (Bar Harbor, ME). The
transgenic mice express chimeric mouse/human APP with the
double mutations (K670N and M671L) and human PS1 with a
deletion of exon 9 found in familial AD patients. Animals were
housed and maintained at the College of Medicine Animal Facility
of the Third Military Medical University. A total of forty-five 10
months old Tg PS1/APPsw mice were randomly assigned to 3
treatment groups in such a manner as there was no significant
intergroup difference in body weight: PBS, Ad-blank, Ad-VIP
(n=15 for each group, 8 mice for histochemical analyses and 7
mice for protein analysis).
The intra-lateral ventricle injections surgery procedure was
accordingwithGiovanni DiCarlo described previously [35]. Briefly,
the mice were weighed, anesthetized with pentobarbital and placed
in a stereotaxic apparatus (51603 dual manipulator lab standard,
Stoelting, Wood Dale, IL). A midsagittal incision was made to
expose the cranium, A hole in the skull was made by a drill 0.5 mm
posterior to the bregma and 1.0 mm right to the midline. A 10 ml
injectionofPBSorrecombinant adenovirus Ad-VIP (1610
11 PFU/
ml) or blank adenovirus, Ad-blank(1610
11 PFU/ml) was made
using a 10 ml syringe (Hamilton, Reno, Nevada) was injected
unilaterally into the right ventricle at the depth of 2 mm at a rate of
1 ml/min. After allowing the needle to remain in place for 5 min,
the needle was slowly raised at a rate of 0.1 cm/min. Two months
after the injection, the experimental animals were terminated to
determine the therapeutic effects of the treatment. All animal
protocols (IACUC: 06513) used for this study were prospectively
reviewed and approved by the Institutional Animal Care and Use
Committee of Third Military Medical University Institutional
Animal Care and Use Committee.
Immunohistochemical and histochemical analyses
Mice were deeply anesthetized with pentobarbital and cardi-
nally perfused with cold PBS followed by 4% paraformaldehyde.
The brain was quickly removed and fixed in 4% paraformalde-
hyde for 16 h.
The brains were then stored overnight in 30% sucrose in 0.1 M
PBS and frozen in Tissue-Teck optimal cutting temperature
compound. coronal sections (35 mm thick) of the brains were cut
on a freezing-stage cryotome and kept in 0.1 M PBS at 4uC.
Sections were subjected to immunohistochemical, histochemical,
and TUNEL staining. For immunohistocheimstry, free floating
immunohistochemistry was performed using avidin-biotin immu-
noperoxidase method (Vector, Burlingame, CA). Endogenous
peroxidase was eliminated by treatment with 1% H2O2/10%
methanol Tris-buffered saline (TBS) for 60 min at room
temperature. After washing with 0.1 M Tirs buffer (pH 7.5) and
0.1 M TBS (pH 7.4), sections were blocked with 5% normal
serum (from the same animal species in which the secondary
antibody was made) in 0.1 M TBS with 0.5% triton-X-100 (TBS-
T) for 60 min at room temperature to prevent non specific protein
binding. The sections were then incubated with primary
antibodies as described above and 6E10 for detection of Ab in
2% serum in TBS-T for 18–48 h at 4uC. The sections were rinsed
in 0.1 M TBS and incubated with biotinylated secondary
antibodies in 2% serum TBS-T for 2 h at room temperature.
Finally, the avidin biotin peroxidase method using 3, 39-
diaminobenzidine as a substrate (Vector, Burlingame, CA) was
performed according to manufacturer’s protocol. For the negative
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sections were counterstained with hematoxylin. For thioflavineS
staining, tissue sections were stained in 1% thioflavine S (Sigma)
and rinsed with 70% ethanol. After washing with H2O, the
sections were mounted in 75% glycerol in H2O. Neuroinflamma-
tion was detected by staining the brain sections with rat anti-
mouse CD11b, rat anti-mouse CD11c, rat anti-mouse CD45,
rabbit anti-mouse GFAP antibodies BD Pharmigen(San Diego,
CA).
Immunofluorescence
Free-floating brain sections were used to analyze Adenovirus
mediated VIP expression, Immunofluorescence detection and
staining for VIP and NeuN was performed using the anti-NeuN
antibody (1:400). Sections were incubated in anti-NeuN antibodies
overnight at 4 C, rinsed in PBS, and incubated for 1 h in
fluorescently labeled secondary antibodies. Sections were washed
three times with PBS. To assess nonspecific labeling, a negative
control sample was processed using the same protocol but with the
primary antibody omitted. Cells were counted with a BX61
microscope (Olympus, Tokyo, Japan) equipped with a digital
camera.
Quantification of buffer soluble and in-soluble brain Ab
by ELISA
the treated Mice(n=7 for each group) were deeply anesthetized
with pentobarbital and cardinally perfused with cold PBS. The
isolated hippocampus and cortex were weighted and then placed
in ice-cold lysis buffer, sonicated on ice for ,3 min, allowed to
stand for 15 min at 4uC, and centrifuged at 15,000 rpm for
15 min. Levels of buffer-soluble and insoluble Ab in the
hippocampus were determined by the Ab42 and Ab40 ELISA kits
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
protocol. Levels of buffer-soluble Ab were expressed as mean
pg/mg of total protein in tissue lysate standard error. Levels of
buffer-insoluble Ab were expressed as mean ng/mg of wet tissue
weight standard error.
TUNEL assay to detect apoptosis
To investigate cytotoxicity possibly associated with the thera-
peutic modalities, brain sections were subjected to Terminal
(TdT)-mediated dUTP-biotin nick end labeling (TUNEL) assay
using the In situ Cell Death Detection Kit (Roche Biochemicals,
Indianapolis, IN) according to the manufacturer’s protocol. Slides
were analyzed using a BX61 microscope (Olympus, Tokyo, Japan)
equipped with a digital camera.
Image analysis
Quantitative image analysis was performed for amyloid deposits
and reactive/activated glial cells immunohistochemistry in Tg
PS1/APPsw mice injected with Recombinant adenovirus Ad-VIP
or blank adenovirus or PBS. Images were performed using an
Olympus BX61 automated microscope, Olympus Fluoview system
and the Image Pro Plus v5 image analysis software (Media
Cybernetics, Silver Spring, MD). Briefly, images of five 35 mm
sections each separated by an approximately 400 mm interval,
starting at 1.3 mm posterior to the bregma to caudal, from each
mouse were analyzed. Both neocortex and hippocampus were
found in all the brain sections and analyzed separately. Stained
areas were expressed as a percentage of total neocortex or
hippocampus, respectively. a threshold optical density was
obtained that discriminated staining from background. Manual
editing of each field was used to eliminate artifacts. Data are
reported as a percentage of immuno-labeled area captured
(positive pixels) divided by the full area captured (total pixels).
Quantitative image analysis was performed by a single examiner
(T.M.) blinded to sample identities. Data were expressed as mean
6 standard error of the mean (SEM) as a bar graph.
Statistical analysis
All data were normally distributed; therefore, in instances of
single mean comparisons, Levene’s test for equality of variances
followed by a t test for independent samples was used to assess
significance. In instances of multiple mean comparisons, ANOVA
was used, followed by post hoc comparison using Bonferonni’s
method. a Levels were set at 0.05 for all analyses. The statistical
package for the social sciences release 10.0.5 (SPSS, Chicago, IL)
was used for all data analyses.
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